HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments
R. Wagner, D. DeGoey, J. Randolph, C. KruegerAllan, M. Matulenko, W. Kati
{"title":"HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments","authors":"R. Wagner, D. DeGoey, J. Randolph, C. KruegerAllan, M. Matulenko, W. Kati","doi":"10.1007/7355_2018_50","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":23098,"journal":{"name":"Topics in Medicinal Chemistry","volume":"112 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Topics in Medicinal Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/7355_2018_50","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
